Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study
Agustin Sancho-Saldana,Anna Gil-Sanchez,Cristina Gonzalez-Mingot,Silvia Peralta,Maria Jose Solana,Pascual Torres, Alba Juanes,Laura Quibus, Emilio Ruiz, Eduardo Sanpedro,Bibiana Quirant-Sanchez,Eva Martinez-Caceres,Cristina Ramo Tello,Silvia Presas-Rodriguez, Sebatian Garcia Rubio,Beatriz Pardinas Baron,Lluis Ramio-Torrenta,Javier Sotoca,Ines Gonzalez-Suarez,Sara Eichau,Jose M. Prieto-Gonzalez,Maria Rosario Blasco Quilez,Julia Sabin-Munoz,Antonio Jose Sanchez-Lopez, Gloria Llorens Calatayud,Carmen Calles,Angel Perez Sempere,Moises Garces,Olga Carmona,Ester Moral,Jose Vicente Hervas,Yolanda Blanco,Nuria Sola-Valls,Nieves Tellez Lara,Lucia Forero,Luis Brieva Journal of Clinical Medicine（2023）
Key words
Multiple Sclerosis,COVID-19,SARS-CoV-2,DMT,seroprevalence
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper